Kimberly-Clark Corporation KMB

Kimberly-Clark has had a rough stretch in the market over the past year, and that weak share performance puts fresh focus on one core issue: whether the current price around US$97 is sensible when you line it up against the cash the business is expected to generate. With investors also watching the pending Kenvue acquisition and related financing steps, the key question now is how those moves feed into the long term cash flow story behind the stock. The share price has fallen 16.5% over the...

Kimberly-Clark (NasdaqGS:KMB) has launched exchange offers and consent solicitations for Kenvue's outstanding notes tied to its pending acquisition. The proposal gives Kenvue bondholders the option to swap existing securities into new Kimberly-Clark issued notes subject to specified terms. The consent solicitations seek bondholder approval to amend certain covenants in Kenvue's current debt documents as part of the transaction process. Kimberly-Clark's move to exchange and amend Kenvue notes...

Kimberly-Clark just logged its 54th straight year of dividend increases, but a shrinking raise, falling free cash flow, and a massive acquisition in progress raise a pointed question for income investors living on those checks.

Rising rates have boomers flocking to Treasuries, but five battle-tested dividend payers with 50-plus years of consecutive increases may offer something bonds simply cannot deliver.

Kimberly-Clark has raised its dividend through every recession of the past two decades, but a $48.7 billion acquisition and free cash flow that already fell short of last year's dividend payment put that streak in genuine jeopardy.

At a Barclays conference this month, Colgate-Palmolive and Kimberly-Clark flagged rising material and freight costs, while Procter & Gamble gave a Supply Chain 3.0 update.

Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the commencement, in connection with its previously announced pending acquisition ("Acquisition") of Kenvue Inc. (NYSE: KVUE) ("Kenvue"), of an exchange offer (each an "Exchange Offer" and, collectively, the "Exchange Offers") for any and all outstanding notes (the "Kenvue Notes") issued by Kenvue for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes")

Colgate-Palmolive has sent dividend checks without interruption since Grover Cleveland's second term, but a 130-year streak and a shrinking North American business now sit in uncomfortable tension with a premium valuation that leaves almost no room for error.

Kimberly-Clark hands retirees a fatter dividend check every quarter, but one look at what sits behind that payout changes the picture fast. Before you choose the bigger yield, consider what happens when the income has to last decades.

Kimberly-Clark just logged 54 straight years of dividend raises, but a closer look at the cash flow statement raises an uncomfortable question about who is actually funding that growing payout.

The Thornburg Investment Income Builder fund’s “nerdy” investment strategy has delivered a one-year return of 29%.

While investors pile into pricey AI darlings, a handful of battle-tested Dividend Kings have quietly slipped to levels that scream value, and Wall Street analysts see serious upside ahead for 2027.

Both Clorox and Kimberly-Clark have raised their dividends for years and offer yields above 5%, but one of them is sitting on a payout that its own management quietly admits may not be sustainable.

Kimberly-Clark (NasdaqGS:KMB) plans to sell assets tied to its planned US$40b acquisition of consumer products group Kenvue. The disposals are aimed at addressing European Union antitrust concerns linked to overlaps in consumer health and personal care brands. Asset sale discussions focus on EU markets where regulators flagged competition issues as part of their ongoing review of the Kenvue deal. Kimberly-Clark's move to sell assets around the US$40b Kenvue deal sits within a broader pattern...

Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift. The real question is whether these picks can hold up long enough to matter.